Literature DB >> 14978281

A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

Bärbel Schröfelbauer1, Darlene Chen, Nathaniel R Landau.   

Abstract

The virion infectivity factor (Vif) accessory protein of HIV-1 forms a complex with the cellular cytidine deaminase APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) to block its antiviral activity. The antiviral property of APOBEC3G is conserved in several mammalian species, but the ability of Vif to block this activity is species-specific. HIV-1 Vif blocks human APOBEC3G but does not block the mouse or African green monkey (AGM) enzyme. Conversely, SIV(AGM) Vif blocks the antiviral activity of AGM but not human APOBEC3G. We demonstrate that the species specificity is caused by a single amino acid difference in APOBEC3G. Replacement of Asp-128 in human APOBEC3G with the Lys-128 of AGM APOBEC3G caused the enzyme to switch its interaction, becoming sensitive to SIV(AGM) Vif and resistant to HIV-1 Vif. Conversely, the reciprocal Lys to Asp switch in AGM APOBEC3G reversed its specificity for Vif. The reversal of biological activity was accompanied by the corresponding switch in the species specificity with which the enzyme physically associated with Vif and was excluded from virions. The charge of the amino acid at position 128 was a critical determinant of species specificity. Based on the crystal structure of the distantly related Escherichia coli cytidine deaminase, we propose that this amino acid is positioned on a solvent-exposed loop of APOBEC3G on the same face of the protein as the catalytic site.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978281      PMCID: PMC374346          DOI: 10.1073/pnas.0307132101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

2.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

3.  Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions.

Authors:  Nathan C Gaddis; Elena Chertova; Ann M Sheehy; Louis E Henderson; Michael H Malim
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

6.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

7.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  179 in total

1.  Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo.

Authors:  Rodolphe Suspène; Marie-Ming Aynaud; Stefanie Koch; David Pasdeloup; Marc Labetoulle; Barbara Gaertner; Jean-Pierre Vartanian; Andreas Meyerhans; Simon Wain-Hobson
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

4.  A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.

Authors:  John S Albin; Rebecca S LaRue; Jessalyn A Weaver; William L Brown; Keisuke Shindo; Elena Harjes; Hiroshi Matsuo; Reuben S Harris
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

5.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

Review 6.  Retroviruses under editing crossfire: a second member of the human APOBEC3 family is a Vif-blockable innate antiretroviral factor.

Authors:  Didier Trono
Journal:  EMBO Rep       Date:  2004-07       Impact factor: 8.807

7.  Controlling lentiviruses: single amino acid changes can determine specificity.

Authors:  Shari M Kaiser; Michael Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

8.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

9.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

10.  Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Authors:  Bärbel Schröfelbauer; Qin Yu; Samantha G Zeitlin; Nathaniel R Landau
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.